Delivery Order SPE2DB22D2007-SPE2DB25FJ3PF
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,035.60 on August 5, 2025, with an ultimate completion date of August 26, 2025. The contract involves the supply of Envarsus XR 1 mg tablets in a 30-tablet quantity under firm fixed-price terms. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and represents a small-value transaction...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Envarsus XR 1 mg tablets in a quantity of 100 units. This competitively awarded, non-set-aside contract carries a ceiling value of $1,718.48 with firm fixed pricing and is scheduled for completion by September 11, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) with a contract ceiling value of $5,135.85. This is a firm fixed-price delivery order with an ultimate completion date of September 10, 2025, and represents no set-aside contract, indicating it was competitively awarded. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $3,423.90 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 4 mg tablets (100-count bottles) on August 25, 2025, with completion scheduled for September 16, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's corporate office in Conshohocken, Pennsylvania. The contract is issued as a child order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,165.05 to AmerisourceBergen Drug Corp for 30 tablets of Envarsus XR 1 mg on July 29, 2025, with an ultimate completion date of August 19, 2025. This firm fixed price delivery order carries no set-aside designation and represents a competitively awarded transaction under the company's larger indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for supply of Envarsus XR 4 mg tablets (100 count) under a firm fixed price contract valued at $2,141.57. This delivery order represents a non-set-aside competitive award, with an ultimate completion date of September 3, 2025. The pharmaceutical products will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Envarsus XR 4 mg tablets (100 count) with a contract value of $6,847.80. This competitively awarded, non-set-aside delivery order is classified as firm fixed price and will be completed by October 6, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen Drug Corp's substantial...
- The Defense Logistics Agency awarded a $2,577.72 delivery order to AmerisourceBergen Drug Corp for 100 tablets of Envarsus XR 1 mg, a pharmaceutical product for immunosuppression. The contract, awarded on July 31, 2025, with completion targeted for August 21, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive procurement. Performance will occur at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,577.72 for Envarsus XR 1 mg tablets (100-count) on September 12, 2025, with an ultimate completion date of October 3, 2025. The contract is structured as firm fixed price with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single transaction under the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Envarsus XR 1 mg tablets (30-count supply) with a ceiling value of $1,553.40. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and has an ultimate completion date of August 18, 2025. The delivery order is being performed from AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order is a child contract issued...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ3PFDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,711.95 to AmerisourceBergen Drug Corp for 100 tablets of Envarsus XR 4 mg on August 4, 2025, with an ultimate completion date of August 25, 2025. This firm fixed price, non-set-aside contract represents a pharmaceutical supply delivery executed under a competitively awarded vehicle. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary operations. This delivery order is executed as a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a $999,999,999.00 ceiling value through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. Envarsus XR is a tacrolimus-based immunosuppressant medication used in transplant recipients, reflecting the broad therapeutic portfolio that AmerisourceBergen provides through its federal contracts to support Defense Health Agency operations and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 8/4/25 |